Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308873 | 0.80 | SCN1A (0.38) | SCN1ASCN5ASCN8ASCN9ACHRNB2 | |
| SCHEMBL20333513 | 0.80 | PIK3CD (0.41) | SCN1ASCN5ASCN8ASCN9ASLC22A12 | |
| SCHEMBL23872895 | 0.77 | HPGD (0.47) | SCN1ASCN5ASCN8ASCN9ACYP1A2 | |
| SCHEMBL21790175 | 0.76 | SCN1A (0.38) | SCN1ASCN5ASCN8ASCN9ACYP1A2 | |
| SCHEMBL20330202 | 0.76 | SCN1A (0.43) | MKNK1SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL22984858 | 0.76 | SCN9A (0.37) | SCN1ASCN5ASCN8ASCN9ACHRNB2 | |
| SCHEMBL2179037 | 0.75 | SMN1; SMN2 (0.65) | CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1094173 | 0.74 | POLB (0.55) | SCN9ASMN1; SMN2 | |
| SCHEMBL31678766 | 0.74 | PTGS1 (0.44) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL30339221 | 0.74 | PTGS1 (0.44) | SCN1ASCN5ASCN8ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787782-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11680058-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-20 | — | — | US | disclosed |
| US-11174247-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-16 | — | — | US | disclosed |
| US-11155535-B2 | — | — | 2021-10-26 | — | — | US | disclosed |
| US-10919881-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-16 | — | — | US | disclosed |
| CN-101772494-B | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2013-05-15 | — | — | CN | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| CN-101772494-A | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680058-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | AGTR2, EDNRA, AGTR1 | HSP90AA1 3932/4885P2RX7 120/4885MKNK1 4131/4885 |
| US-10919881-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | AGTR2, EDNRA, AGTR1 | HSP90AA1 3932/4885P2RX7 120/4885MKNK1 4131/4885 |
| US-11155535-B2 | — | AGTR2, AGTR1, AGT | HSP90AA1 4308/4885P2RX7 152/4885MKNK1 3069/4885 |
| US-11174247-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | AGTR1, AGTR2, EDNRA | HSP90AA1 4416/4885P2RX7 90/4885MKNK1 3164/4885 |
| US-11787782-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | AGTR1, AGTR2, EDNRA | HSP90AA1 4416/4885P2RX7 90/4885MKNK1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.